- Willis Towers Watson’s adjusted earnings per share (EPS) for the first quarter were $3.13, falling short of the estimated $3.23.
- The company’s revenue totaled $2.22 billion, which was below the anticipated $2.28 billion.
- The Health, Wealth & Career segment generated $1.17 billion in revenue.
- The Risk & Broking segment reported revenues of $1.03 billion.
- Risk & Broking saw an organic revenue growth of 7%, exceeding the expected 6.35% increase.
- The adjusted operating margin reached 21.6%, slightly above the 21.2% estimate.
- Health, Wealth & Career achieved an operating margin of 26.7%, surpassing the expected margin of 26.3%.
- The Risk & Broking operating margin was 22%, beating the estimate of 21.8%.
- Analyst recommendations comprised 14 buys, 4 holds, and 2 sells.
A look at Willis Towers Watson Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Willis Towers Watson’s long-term outlook, as indicated by its Smartkarma Smart Scores, reflects a positive momentum with a score of 4. This suggests that the company is performing well relative to its peers in terms of market momentum. Additionally, with a growth score of 3, Willis Towers Watson shows promising signs of expansion and development in the foreseeable future. Despite having average scores in value, dividend, and resilience, the company’s strengths in growth and momentum bode well for its overall outlook.
Summary: Willis Towers Watson Public Limited Company operates as an advisory, broking, and solutions company in the insurance industry. With a global presence, the company offers a range of insurance brokerage, reinsurance, and risk management consulting services to customers worldwide.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
